Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis
2024 · Osteoporosis International · 13 citations
https://doi.org/10.1007/s00198-024-07161-x